Outcomes in Psoriasis Clinical Trials from January 2011 to March 2012

Sampogna, Francesca; Abeni, Damiano

doi:10.1007/s13671-012-0019-5

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 PASI is one of the most commonly used outcome measures in clinical trials to evaluate treatment response, as it allows for a direct comparison of results. 12,13 Speed of response of a biologic agent can be determined by analyzing PASI responder rates over time. For example, speed of onset can be determined by analyzing the average time required for subjects to achieve PASI 25 or PASI 50, or perhaps by assessing the average PASI improvement obtained at 2 or 4 weeks of treatment.…”

Section: Introductionmentioning

confidence: 99%

Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials

Johnson

Heron

Ghamrawi

et al. 2021

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Background: Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response. Objective: We evaluated clinical trial data to determine which biologic agents achieve the fastest treatment response. Methods: A review of phase III clinical trials of biologic agents in psoriasis was performed. Speed was determined by analyzing Psoriasis Area and Severity Index (PASI) 75/90 responder curves to estimate the point at which 50% of subjects achieved that outcome, PASI 75/9050. Time to achieve PASI 75/9050 was averaged across trials. Results: Time to achieve PASI 7550, in weeks: brodalumab 210 mg, 3.5; ixekizumab 80 mg Q2 W, 4; secukinumab 300 mg, 5; infliximab 5mg/kg, 5.5; risankizumab 150 mg, 6; guselkumab 100 mg, 6.25; adalimumab 40 mg, 7.25; ustekinumab 45/90 mg, 7.4; certolizumab 400 mg, 7.5; tildrakizumab 100 mg, 9; etanercept 50 mg, 12.5. PASI 9050 responder rate estimations revealed a similar trend. Conclusion: Interleukin-17 inhibitors have a more rapid treatment response compared with other classes. Although speed is important, efficacy, persistence, side effects, cost of treatment, and number of injections are all factors to consider.

show abstract

Section: Introductionmentioning

confidence: 99%